aH5N1c
Biological
Seqirus USA Inc
Total Payments
$4.4M
Transactions
140
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $4.4M | 140 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 140 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age | Seqirus USA Inc | $4.4M | 0 |
Top Doctors Receiving Payments for aH5N1c
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $4.4M | 140 |
Ad
Manufacturing Companies
- Seqirus USA Inc $4.4M
Product Information
- Type Biological
- Total Payments $4.4M
- Total Doctors 0
- Transactions 140
About aH5N1c
aH5N1c is a biological associated with $4.4M in payments to 0 healthcare providers, recorded across 140 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2017. In 2017, $4.4M was paid across 140 transactions to 0 doctors.
The most common payment nature for aH5N1c is "Unspecified" ($4.4M, 100.0% of total).
aH5N1c is associated with 1 research study, including "A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age" ($4.4M).